医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZELTIQ® Aesthetics to Showcase CoolCurve+ Applicator at IMCAS Asia Hong Kong 2012

2012年10月04日 AM09:11
このエントリーをはてなブックマークに追加


 

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced Henry H. Chan, MD, PhD, FRCP, will perform a live demonstration of CoolCurve+, the newest addition to the applicator platform for the CoolSculpting® System, at the International Master Course on Aging Skin (IMCAS) Asia in Hong Kong on October 5, 2012. Developed for enhanced fit and tissue draw, the anatomically curved shape of the CoolCurve+ applicator allows physicians to treat a multitude of body shapes.

WHAT:

    Session 22 – Lasers, Lights, Energy-Based Devices
Live CoolSculpting Demonstration with CoolCurve+ Applicator
 

WHEN:

Friday, October 5, 10:10-10:30 a.m.
 

WHERE:

International Master Course on Aging Skin (IMCAS) Asia
InterContinental Hong Kong Hotel
18 Salisbury Road, Kowloon, Hong Kong SAR
Room 3
 

WHO:

Henry H. Chan, MD, PhD, FRCP

 

For more information about CoolCurve+ and CoolSculpting, visit ZELTIQ Aesthetics at Booth B08. Exhibition hours are as follows: Friday, October 5, 8:30 a.m. to 6 p.m.; Saturday, October 6, 8:30 a.m. to 2 p.m.

About ZELTIQ Aesthetics, Inc.

ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

CONTACT

Neo Derm for ZELTIQ
Colin Leung
+852 9303 0338
colin.leung@neoderm.com.hk

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表